ESMO Congress 2024
September 13 – 17, 2024
Barcelona, Spain
BOOTH #608 Connect with Caris Life Sciences during ESMO Congress
Join Caris Life Sciences at the European Society for Medical Oncology (ESMO) in Barcelona, Spain. Visit us at booth #608 to uncover the latest breakthroughs in precision medicine. The findings demonstrate the power of Caris’ comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan and response to treatment.
- Comprehensive molecular profiling – no matter the specimen type, tissue or blood:
- Tissue: DNA, RNA and Protein biomarker analysis
- Blood: Caris Assure™ featuring somatic tumor, clonal hematopoiesis and incidental germline* characterization
- Whole exome and whole transcriptome sequencing for every patient
- 23,000 genes via Whole Exome Sequencing (WES – DNA)
- 61,000 transcripts via Whole Transcriptome Sequencing (WTS – RNA)
- AI-Powered Predictive Signatures for metastatic CRC and tumor type confirmation
- Accelerate therapeutic development with Caris Discovery™
- Identify, develop and commercialize your next therapeutic targets
- Make confident decisions with real-world, multi-modal data
Presentations and Posters
Caris and its collaborators from the biopharma industry and leading cancer centers, including those within the Precision Oncology Alliance™ (POA), will collectively present seven studies across a wide range of tumor types during ESMO.
MINI ORAL PRESENTATIONS:
- Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1,
BRCA2, or PALB2 pathogenic variants: Real world data analysis of genomics and targeted
therapy sequencing
(Abstract Number: #342MO)
Sunday, September 15; 8:35-8:40 AM CEST - Atlas of tertiary lymphoid structures in solid tumors: Genomic features and prediction of
response to immunotherapy
(Abstract Number: #75MO)
Monday, September 16; 9:40-9:45 AM CEST
POSTER PRESENTATIONS:
- Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with
immune checkpoint inhibitors
(Abstract Number: #1051P)
Saturday, September 14; 12:00-1:00 PM CEST - Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the
assessment of endometrial endometrioid adenocarcinoma (EEA)
(Abstract Number: #739P)
Saturday, September 14; 12:00-1:00 PM CEST - METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker
presence
(Abstract Number: #1303P)
Saturday, September 14; 12:00-1:00 PM CEST - Genomic landscape & prognostic impact of HER2 low-expressing tumors
(Abstract Number: #126P)
Sunday, September 15; 12:00-1:00 PM CEST - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer
(PC)
(Abstract Number: #1653P)
Sunday, September 15; 12:00-1:00 PM CEST
Caris Abstracts and Presentation Schedule
Caris’ strong presence at ESMO 2024 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Download the abstracts and presentation schedule, including a full list of summaries highlighting the research presented at ESMO 2024.
Certain products and features may vary based on region or territory.
*Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.